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INTRODUCTION
Thyroid-stimulating hormone (TSH), insulin, and insulin
like growth factor-1 (IGF-I) stimulate cell cycle progression
and proliferation in various thyrocyte culture systems, includ-
ing established rat thyroid cell lines (FRTL-5, WRT, and
PC Cl3) and primary cultures of rat, dog, sheep, and human
thyroid (1). TSH regulates thyrocyte proliferation via acti-
vation of cAMP-dependent and cAMP-independent signal-
ing pathways, which involve protein kinase A, phosphatidyli-
nositol 3 (PI3)-kinase, and RAS (1-5). TSH is not only involv-
ed in the proliferation of thyroid cells, but is also associated
with the maintenance of differentiated functions, such as
regulation of thyroglobulin and thyroperoxidase gene expres-
sion (6-9). The signaling pathways activated by TSH are
associated with the induction and activation of a number of
thyroid-specific and ubiquitous transcription factors, which
transcribe a set of genes that control thyrocyte proliferation
and maintenance of function. Specifically, TSH (5-9) and
insulin (8-11) regulate thyroid-specific transcription factors,
such as TTF-1, TTF-2, and Pax-8, and these transcription
factors are critically involved in the transcriptional regula-
tion of thyroglobulin (Tg), thyroperoxidase (TPO), TSH
receptor (TSHR) (7, 8, 10), and the sodium iodide symporter
(12, 13).
Inhibitors of differentiation (Id) proteins are small helix-
loop-helix proteins that lack a DNA binding region. Usual-
ly these proteins interact with basic helix-loop-helix (bHLH)
proteins and act as negative regulators by preventing their
DNA binding and transcriptional activities (14). Four mam-
malian members of the Id protein that have been identified
to date exhibit 69-78% identity at the amino acid level with-
in their HLH dimerization domains, but other regions of
these proteins are essentially unrelated (15). Id family pro-
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Regulation of Inhibitors of Differentiation Family Proteins by Thyroid-
Stimulating Hormone in FRTL-5 Thyroid Cells
Members of the inhibitors of differentiation (Id) family of helix-loop-helix (HLH) pro-
teins are known to play important roles in the proliferation and differentiation of many
cell types. Thyroid-stimulating hormone (TSH) regulates proliferation and differen-
tiation by activating TSH receptor (TSHR) in thyrocytes. In this study, we found that
Id2, one of the Id family proteins, is a major target for regulation by TSH in FRTL-5
thyroid cells. TSH rapidly increases the Id2 mRNA level in FRTL-5 thyroid cells but
the Id2 protein showed biphasic regulatory patterns, being transiently reduced and
subsequently induced by TSH treatment. Transient reduction of Id2 protein was
noted within 2 hr of TSH treatment and was mediated by proteasomal degradation.
Moreover, reduced Id2 expression correlated with the activity of the phosphatidyli-
nositol 3 kinase pathway, which is activated by TSH. Although TSH increases the
activity of the Id2 promoter, TSH-induced activation of this promoter was indepen-
dent of c-Myc. Id2 did not alter TTF-1- and Pax-8-mediated effects on the regula-
tion of the Tg promoter. Thus, in summary, we found that TSH regulates Id2 expres-
sion, but that Id2 does not alter the expression of thyroid-specific genes, such as
Tg, in FRTL-5 thyroid cells.
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teins are important in the regulation of various cellular pro-
cesses, including cellular proliferation, death, and differenti-
ation (14, 16-24). Recent studies have revealed that Id pro-
teins bind to pRB (retinoblastoma tumor suppressor protein)
family proteins and Ets-family transcription factors, which
are known to play key roles in cell cycle regulation, transfor-
mation, and tumor suppression (20-23).
Although the expression of Id family proteins is elevated
in proliferating cells and down-regulated during differenti-
ation, the precise pattern of their regulation is highly depen-
dent on the cell type (22-25). In this report, we have inves-
tigated Id family protein expression in FRTL-5 thyroid cells
following exposure to TSH and have demonstrated the effects
of Id family proteins on the transcriptional activities of the
thyroid-specific transcriptional factors, TTF-1 and Pax-8.
MATERIALS AND METHODS
Materials 
Highly purified bovine TSH (Sigma Chemical Co., St.
Louis, MO, U.S.A.), [ -32P] dCTP (3000 Ci/mM) (DuPont-
Merck Pharmaceutical Co., Wilmington, DE, U.S.A.), Wort-
mannin, LY294002 and H89 (Calbiochem, La Jolla, CA,
U.S.A.), Rapamycin (Sigma Chemical Co.), and PD98059
(New England Biolabs, Beverly, MA, U.S.A.) were obtained.
All other materials were from Sigma Chemical Co., unless
otherwise noted.
Cells 
FRTL-5 rat thyroid cells (Interthyroid Research Founda-
tion, Baltimore, MD, U.S.A.) were a fresh subclone (F1) that
had all properties detailed previously (26). Their doubling
time in the presence of TSH was 36±6 hr, and in the absence
of TSH they did not proliferate. After 6 days in medium
lacking TSH, the addition of 1×10-10 M TSH stimulated
thymidine incorporation into DNA by at least 10-fold. Cells
were diploid and between their 5th and 20th passage. They
were grown in 6H medium consisting of Coon’s modified
F12 supplemented with 5% calf serum, 1 mM nonessential
amino acids, and a mixture of six hormones (6H): bovine
TSH (1 mU/mL), insulin (10  g/mL), cortisol (0.4 ng/mL),
transferrin (5  g/mL), glycyl-L-histidyl-L-lysine acetate (10
ng/mL), and somatostatin (10 ng/mL). The medium was replac-
ed every 2 or 3 days and cells were passaged every 7-10 days.
In individual experiments, cells were shifted to 0H medium
(devoid of 6 hormones described above) and 5% calf serum.
COS7 kidney fibroblasts were maintained in Dulbecco’s mod-
ified Eagle’s medium (high glucose) supplemented with
penicillin-streptomycin and 10% fetal bovine serum (FBS)
(GIBCO-BRL, Carlsbad, CA, U.S.A.). 
Plasmids 
The promoter reporter construct of the Id2 gene, pGId2-
2750, was supplied by Dr. Lavarone A (22). The mutant Id2
promoter construct, pGId2-2750 del (EcoR1), was made by
deletion of the EcoR1 fragment (1,330-2,230 bp) that contains
high-affinity Myc-binding sites. GAL4-Id fusion constructs
were generated by cloning cDNAs of Id1, Id2, Id3, and Id4
into pBind. The thyroglobulin promoter constructs, -808
Tg-pGL3, -688 Tg-pGL3, and -207 Tg-pGL3 were suppli-
ed by Dr. S. Kimura. The expression vectors, pRc/CMV-TTF1
and pRc/CMV-Pax-8 (7), were kindly provided by Dr. Kohn
L.D. All plasmids were prepared using a Plasmid Maxi Kit
(QIAGEN, Chatsworth, CA, U.S.A.).
Northern blotting 
Total RNA was extracted from FRTL-5 rat thyroid cells
cultured in a 10-cm dish following exposure to TSH or in-
sulin as described previously (27). Approximately 20  g total
RNA was fractionated on a 1% formaldehyde-agarose gel.
After fractionation, the RNA was transferred to a nylon mem-
brane (Hybond
+ N, Amersham Pharmacia Biotech, Piscat-
away, NJ, U.S.A.) in 10×SSC buffer and UV-cross-linked as
described previously (27). The membranes were then prehy-
bridized in Quick Hybridization buffer (Stratagene, La Jolla,
CA, U.S.A.) for 1 hr at 69℃, following which the hybridiza-
tion was carried out at 69℃ for 24 hr with 32P-labeled Id
probes. Membranes were washed for 15 min at room temper-
ature in wash buffer A (2X SSC and 0.1% sodium dodecyl
sulfate [SDS]), and for 15 min at higher stringency tempera-
ture in wash buffer B (0.1×SSC and 0.1% SDS). All probes
were radiolabeled using a random priming protocol (Amer-
sham Pharmacia Biotech). The labeled probes used were the
full length cDNA for rat Id1, Id2, Id3, Id4, and  -actin. 
Immunoblot analysis 
Immunoblot analysis was performed using anti-Id (Santa
Cruz Biotechnology, Santa Cruz, CA, U.S.A.) antibodies.
Adherent FRTL-5 cells were stimulated with various agents
for the indicated period of time at 37℃. The treated cells
were scraped, lysed by addition of SDS sample buffer (62.5
mM Tris-HCl [pH 6.8], 6% [w/v] SDS, 30% glycerol, 125
mM DTT, 0.03% [w/v]bromophenol blue) and separated by
10% SDS-PAGE, along with biotinylated molecular weight
standards. The proteins were transferred to a nitrocellulose
membrane by electrotransfer for 2 hr. After soaking in block-
ing buffer (1×TBS, 0.1% Tween-20, 5% milk) the mem-
brane was incubated with primary antibody overnight at 4℃.
Blots were developed using the HRP-linked secondary anti-
body and a chemiluminescent detection system (Phototope
�-
HRP Western Blot Detection Kit, New England Biolabs,
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Transient transfection and luciferase assay 
Cells were transfected by the LipofectAMINE method
(Invitrogen, Carlsbad, CA, U.S.A.) according to the manu-
facturer’s instructions. Briefly, 400 ng of promoter reporter
construct (Fig. 7A) was incubated in serum-free media with
6  L LipofectAMINE Plus reagent at room temperature for
15 min; 4  L LipofectAMINE reagent was added and the
mixture was incubated at room temperature for a further 15
min. Semiconfluent cells were washed twice with 1× PBS
(phosphate-buffered saline) and incubated with DNA-Lipo-
fectAMINE Plus reagent complexes at 37℃in a humidified
chamber containing 5% CO2 for 4 hr. All DNA constructs
were transfected with 100 ng pRL-SV40 plasmid encoding
Renilla luciferase (Promega, Madison, WI, U.S.A.) to adjust
the transfection efficiency. Following transfection, cells were
allowed to recover for 24 hr following which they were wash-
ed with 1×PBS and lysed with 100  L lysis buffer contain-
ing 40 mM Tricine (pH 7.8), 50 mM NaCl, 2 mM EDTA,
1 mM MgSO4, 5 mM DTT, and 1% Triton X-100. Extracts
were assayed in triplicate for luciferase activity in a total vol-
ume of 130  L containing 30  L cell extract, 20 mM tricine,
0.1 mM EDTA, 1 mM magnesium carbonate, 2.67 mM
MgSO4, 33.3 mM DTT, 0.27 mM coenzyme A, 0.47 mM
luciferin, and 0.53 mM ATP, and light intensity was mea-
sured using a luminometer (Berthold, Bad Wildbad, Ger-
many). Firefly and Renilla luciferase activities were measured
using a Dual-Luciferase Reporter assay system (Promega,
Madison, WI, U.S.A.) and a model TD-20/20 Luminome-
ter. Luciferase activity was integrated over a 10-sec period.
Firefly luciferase values were standardized to Renilla values.
GAL4 hybrid assays 
The pG5-luc reporter plasmid contains five GAL4-bind-
ing sites upstream of the coding sequence with a minimal
thymidine kinase region for luciferase assay. The GAL4-fusion
protein expression plasmids; pBind-Id1, pBind-Id2, pBind-
Id3, and pBind-Id4 were coexpressed with the pG5-luc reporter
in FRTL-5 thyroid cells. Transfected cells were treated with
or without 1 mU TSH for 12-24 hr and assayed for luciferase
activity as previously described (28). 
RESULTS
Regulation of Id RNA expression by TSH and insulin in
FRTL-5 cells 
Expression of Id transcripts was observed in FRTL-5 thy-
roid cells following treatment with TSH (1 mU/mL) and
insulin (10 ng/mL) (Fig. 1). Id2 and Id4 mRNA expression
was increased by TSH (1 mU/mL) treatment; however Id1
and Id3 were not modulated. The induction of Id2 mRNA
by TSH was rapid and prolonged. Its maximal level was reach-
ed within 1 hr and this level was maintained for 12 hr (Fig. 1A).
Id4 mRNA was also rapidly induced (within 1 hr) by TSH
treatment but returned to its basal level by 6 hr. Different
patterns of Id RNA expression were observed in insulin-treat-
ed cells. The TSH-responsive Id2 did not respond to insulin,
whereas Id1 and Id4 RNA increased following exposure to
insulin, and Id3 mRNA expression was virtually unaffected.
Regulation of Id protein levels by TSH in FRTL-5 thyroid
cells 
Since the Id RNA expression studies suggested that Id2
is a major TSH-responsive gene, we investigated Id2 pro-
tein levels in FRTL-5 cells following TSH treatment. Id2
protein was regulated biphasically in response to TSH treat-
ment. As shown in Fig. 2A, Id2 was expressed basally in
untreated FRTL-5 thyroid cells; however, the level of Id2
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Fig. 1. Effects of TSH and insulin on Id family RNA levels in cultured
FRTL-5 cells. A, B FRTL-5 thyroid cells were grown to near con-
fluency in Coon’s modified Ham’s F-12 medium containing 5%
(v/v) calf serum. The cells were starved for 6 days with 0H medi-
um and 5% calf serum which did not contain hormones. The cells
were treated with TSH 1 mU/mL (A) and insulin 10  g/mL (B). Total
RNA was isolated from 1 to 12 hr after the final treatment and sub-
jected to Northern analysis (20  g/lane) using Id family and  -
actin cDNA probes as described in Materials and Methods. The
amount of RNA in each lane was monitored using  -actin. The
results are representative of a minimum of three independent ex-
periments. Regulation of Id Proteins by TSH 265
rapidly decreased within 2 hr of TSH treatment and subse-
quently recovered to the basal level. After an 8-hr exposure
to TSH, the expression of Id2 was higher than that of untreat-
ed cells. The influence of TSH on FRTL-5 cell signaling was
further monitored by detection of S6 ribosomal protein phos-
phorylation (4, 5). This phosphorylation event reflects the
activity of S6 kinase, which is activated by both TSH and
forskolin in thyroid cells (Fig. 2). Phosphorylation of ribo-
somal S6 protein was observed in TSH-treated cells within
1 hr and was maintained for 12 hr. In a similar experiment,
forskolin induced a transient decrease of Id2 protein expres-
sion that coincided with the TSH-mediated activation of S6
kinase. Insulin also transiently decreased Id2 protein expres-
sion during the S6 kinase activation phase. 
Previously, it has been shown that Id family proteins are
short-lived proteins whose degradation is dependent on the
proteosomal pathway (29). As shown in Fig. 2A, Id2 was
rapidly down-regulated, which suggested that Id2 proteins
would also be degraded by the proteasomal pathway in res-
ponse to TSH treatment. To investigate this, we pretreated
FRTL-5 rat thyroid cells with or without MG132, a specific
proteosome inhibitor (30, 31), prior to TSH treatment. MG132
completely blocked Id2 degradation induced by TSH or
forskolin treatment (Fig. 3). These results strongly support
the hypothesis that TSH- and forskolin-induced Id2 degra-
dation is mediated by the proteosomal pathway. 
The phosphatidylinositol 3 kinase pathway is involved in
TSH-mediated Id2 degradation
Given that the transient decrease of Id2 level in TSH-treat-
ed cells occurred during the activation phase of S6 kinase,
we hypothesized that PI3 kinase may be involved in TSH-
mediated Id2 degradation in thyroid cells. Moreover, activa-
tion of S6 kinase by TSH is dependent on PI3 kinase, mTOR,
and PKA in thyroid cells (1-5). To identify the involvement
of PI3 kinase, mTOR and PKA signaling in TSH-induced
Id2 degradation, the cells were pretreated with the specific
inhibitors LY294002, wortmannin, rapamycin, H89, and
PD98059 (3, 4) for 2 hr prior to incubation with TSH or
forskolin. Both LY294002 and wortmannin, which are spe-
cific PI3 kinase inhibitors, prevented TSH-mediated Id2
degradation (Fig. 4A, B). However, rapamycin, a specific
inhibitor of mTOR, and H89, a PKA inhibitor, had no effect
on Id2 degradation (Fig. 4C). PD98059, a MAPK inhibitor,
also had no effect on TSH-induced Id2 degradation (data not
shown). These results indicate that PI3 kinase pathways are
involved in TSH-induced proteosomal degradation of Id2. 
Regulation of Id2 promoter activities by TSH in FRTL-5
thyroid cells 
In the above studies, we found that Id2 mRNA was induc-
ed by TSH treatment, and that its protein level was also up-
regulated after 8 hr by TSH treatment. To confirm if Id2
promoter activity is regulated by TSH, we transfected FRTL-
5 cells with pGId2-2750, a luciferase reporter that contained
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Fig. 2. Effects of TSH, forskolin, and insulin on Id family protein levels
in cultured FRTL-5 cells. A, B, C FRTL-5 thyroid cells were grown
to near confluency in Coon’s modified Ham’s F-12 medium con-
taining 5% (v/v) calf serum. The cells were starved for 6 days with
0H medium and 5% calf serum which did not contain hormones
and were then treated with TSH 1 mU/mL (A), forskolin 10  M (B),
and insulin 10  g/mL (C). The samples were subjected to SDS-
PAGE and transferred to a nitrocellulose membrane. The protein
levels of Id2 were detected using a specific antibody.  -actin was
used to monitor protein loading. The phosphorylation of S6 ribo-
somal protein (S6P) reflects the activity of S6 kinase, which is acti-
vated by TSH, forskolin, and insulin in thyroid cells. The results are
representative of a minimum of three independent experiments. 
01 2 401 2 4
DMSO MG132
Id 2
-actin
hr
TSH
(1 mU/mL) A
Fig. 3. TSH-induced Id2 degradation by the proteosomal pathway.
A, B FRTL-5 thyroid cells were grown to near confluency in Coon’s
modified Ham’s F-12 medium containing 5% (v/v) calf serum. The
cells were starved for 6 days with 0H medium and 5% calf serum
which did not contain hormones. The cells were pretreated without
or with MG132 (10  M) for 2 hr, incubated for an additional  indicat-
ed time with TSH (1 mU/mL) (A) or forskolin (10  M) (B). Cell lysates
were separated by SDS-PAGE and transferred to a nitrocellulose
membrane. The protein levels of Id2 were detected using an Id2-
specific antibody.  -actin was used to monitor protein loading. The
results are representative of a minimum of three independent experi-
ments. 
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-2,750 bp of the 5’-region of the mouse Id2 gene (22) and
measured its activity following TSH treatment. The high
affinity Myc-binding sites (CACATG at position -1,880 and
CACGTG at position -1,950) in the Id2 promoter are shown
in Fig. 5A. These E-boxes are known to be important sites
for Myc-mediated transactivation of the Id2 promoter dur-
ing serum-mediated fibroblast stimulation (22). The con-
struct, pGId2-2750 del (1330-2230), did not contain the
Myc-binding sites. TSH increased not only wild-type pGId2-
2750 promoter activities, but also increased the activity of
the mutant pGId2-2750 del (1330-2230) that is devoid of
Myc-binding sites. Although several studies suggested that
TSH can induce c-Myc expression in thyroid cells, these
results suggest that induction of Id2 promoter activities in
FRTL-5 thyroid cells by TSH may not depend on c-Myc. 
Regulation of transcriptional activities of Id proteins and
effects of Id2 protein on TTF-1/Pax-8 activity in FRTL-5 cells
In the above study, we found that TSH regulates the induc-
tion of Id2 promoter activity, mRNA and protein expression
in FRTL-5 thyroid cells. All four Id family proteins possess
related HLH dimerization domains that can interact with
similar bHLH proteins. Recent studies suggested that Id
family proteins are phosphorylated and have transcriptional
activities (32). We tested the effects of TSH on the transcrip-
tional activities of Id proteins using GAL4-dependent tran-
scriptional systems. GAL4 fusion protein expression plas-
mids, GAL4-Id1, GAL4-Id2, GAL4-Id3, and GAL4-Id4,
were co-transfected with the reporter plasmid pG5-luc, and
reporter activities were monitored in the presence or absence
of 1 mU TSH. As shown in Fig. 6, GAL4-Id1, GAL4-Id3,
and GAL4-Id4 proteins did not activate GAL4-dependent
transcription. GAL4-Id2 protein had weak, albeit signifi-
cant, transcriptional activity, but this was not modulated by
TSH. These observations suggest that TSH signaling does
not directly affect Id2-mediated transcriptional activity in
FRTL-5 thyroid cells.
Fig. 4. Involvement of PI3 kinase in TSH-induced Id2 proteosomal
degradation. FRTL-5 thyroid cells were grown to near confluency in
Coon’s modified Ham’s F-12 medium containing 5% (v/v) calf serum.
The cells were starved for 6 days with 0H medium and 5% calf serum
which did not contain hormones. (A, B) The cells were pretreated
with PI3 kinase inhibitors LY294002 (500 nM) (A) or wortmannin
(100 nM) (B) for 2 hr prior to being exposed to TSH (1 mU) or fors-
kolin (10  M). (C) Cells were pretreated with rapamycin (20 nM) for
2 hr and again were exposed to TSH (1 mU) or forskolin (10  M)
for 30 min. (D) Cells were pretreated with H89 (50  M) for 2 hr and
then incubated with TSH (1 mU) or forskolin (10  M) for an addi-
tional 2 hr before being lysed. Cell lysates were separated by SDS-
PAGE and transferred to a nitrocellulose membrane. The protein
levels of Id2 were detected using an Id2-specific antibody.  -actin
was used to monitor protein loading. LY, LY294002 (500 nM); W,
Wortmannin (100 nM); R, Rapamycin (20 nM); H89 (50  M). The
results are representative of a minimum of three independent experi-
ments. 
Fig. 5. TSH-induced Id2 promoter activity does not require the Myc
binding element. (A) Wild-type and deletion constructs of the Id2
promoter. (B) FRTL-5 thyroid cells were grown to near confluency
in Coon’s modified Ham’s F-12 medium containing 5% (v/v) calf
serum. FRTL-5 cells were starved for 6 days with 0H medium and
5% calf serum which did not contain hormones. The cells were tran-
siently transfected with wild-type or deletion mutant reporter plas-
mids following which they were treated with TSH (1 mU/mL) for 12
hr and assayed for luciferase activity as described in Materials and
Methods. The fold-induction was calculated by dividing the luciferase
activity of the TSH-treated samples by the luciferase activity of the
medium-treated sample. The results are represented as the mean
±SD from at least three experiments.
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Id proteins have been shown to interact with Pax family
transcription factors, such as Pax-2/-5/-8, and to inhibit the
DNA binding of Pax transcription factors (24). Pax-8 is a
thyroid-limited transcription factor, which is involved in
normal thyroid development and transcriptional regulation
of the thyroid-specific genes Tg, TPO, and sodium iodide
symporter (NIS) (4-8, 13). To determine whether Id2 is in-
volved in regulating transcription of the Tg gene, we cotrans-
fected the Tg promoter constructs, -808 Tg-pGL3, -688 Tg-
pGL3, and -207 Tg-pGL3, with or without the expression
plasmid constructs pCDNA3-Id2 into FRTL-5 cells. As shown
in Fig. 7A, Id2 did not change the reporter activities of -808
Tg pGL3, -688 Tg pGL3, or -207 Tg pGL3, which has bind-
ing motifs for Pax-8 and TTF-1. In addition, in Cos-7 cells,
Id2 did not affect TTF-1-mediated or Pax-8-mediated Tg
gene transcription (Fig. 7B, C). These observations suggest
that Id overexpression may not alter the expression of thy-
roid-specific genes such as Tg in thyroid cells. 
DISCUSSION
In the present study, we investigated the regulation of
expression and functions of Id family proteins in FRTL-5
thyroid cells. We found that the expression of Id2, is up-reg-
ulated by TSH in FRTL-5 thyroid cells. At the protein level,
the regulation of Id2 by TSH was biphasic, starting with a
transient decrease followed by a delayed increase in expres-
sion, although Id2 mRNA was rapidly induced by TSH. The
transient decrease of Id2 protein expression was not specific
to TSH, but was also observed following insulin treatment.
Moreover, the rapid degradation of Id2 by TSH was prevent-
ed by MG132, a specific proteosome inhibitor (30, 31). This
observation suggests that TSH may modulate the activities
of E1 ubiquitin enzyme systems. 
PI3 kinase signaling pathways are involved in regulating
differentiation in many cell types (4, 5, 33, 34) and are also
involved in protein degradation (32, 34-36). For example,
insulin-induced IRS-1 degradation requires the PI3 kinase
pathway (31, 35, 36). As shown in Fig. 4, the specific PI3
Fig. 7. Effect of overexpression of Id2 on thyroglobulin promoter activity. (A) After FRTL-5 cells were grown to near confluency in complete
6H medium with 5% serum, the cells were starved for 6 days with 0H medium and serum. The -808 Tg-PGL3, -688 Tg-PGL3, and -207 Tg-
PGL3 plasmids were co-transfected into FRTL-5 cells with the expression vector encoding pCDNA3-Id2. After transfection, the cells were
cultured in 6H medium with 5% serum for 12 hr, and were subjected to luciferase assay. (B, C) Cos7 cells were transiently transfected with
-808 Tg-PGL3, the expression vector encoding pRc/CMV-TTF-1 (B), or pRc/CMV-Pax8 (C) and increasing concentrations of Id2 as indicat-
ed. Cells were cultured in DMEM containing 10% FBS for 12-24 hr and assayed for luciferase activity as described in Materials and Methods.
The fold-inductions are expressed relative to luciferase activity obtained after transfection of the -808 Tg-PGL3 vector, arbitrarily set at 1. The
results are represented as the mean±SD from at least three experiments.
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Fig. 6. Transactivation of Id family members by TSH in cultured
FRTL-5 cells. FRTL-5 cells were starved for 6 days with 0H medi-
um and 5% calf serum which did not contain hormones. pBind-1,
pBind-Id2, pBind-Id3, or pBind-Id4 (400 ng) were transiently cotrans-
fected with 400 ng of the reporter plasmid pG5-tk-luc into FRTL-5
cells. Cells were cultured in the presence or absence of TSH (1
mU/mL) for 12-24 hr and collected for luciferase assay. The fold-
inductions are expressed relative to luciferase activity obtained
after cotransfection of the GAL-empty vector, arbitrarily set at 1.
The results are represented as the mean±SD from at least three
experiments.
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kinase inhibitors, LY 294002 and wortmannin, prevented
TSH-induced Id2 degradation in FRTL-5 cells (Fig. 4). Sev-
eral studies have suggested that TSH activates PI3 kinase-
dependent signaling pathways to regulate thyrocyte prolif-
eration (1-5). We propose that PI3 kinase pathways that are
activated by TSH may be responsible for the degradation of
specific proteins, such as Id2, in thyroid cells. However, the
biological significance of the transient reduction of Id2 in
TSH-activated thyroid cells was not fully evaluated in this
study. 
The expression of Id2 is transcriptionally regulated through
the activation of several transcription factors, such as c-Myc
(22). The human Id2 promoter contains a cluster of three E-
boxes that are high-affinity Myc-binding sites (CACATG at
position -1,880 and CACGTG at position -1,590) (22). TSH
and cAMP both enhance the expression of the c-Myc proto-
oncogene in cultured thyroid cells (37). We further tested
whether the Id2 promoter activation was under the direct
control of c-Myc in FRTL-5 cells. However, the inducibility
of a mutant Id2 promoter, which has no Myc-binding sites,
by TSH was comparable to the wild-type Id2 promoter. These
findings suggest that Id2 induction by TSH may not involve
c-Myc-dependent transcriptional mechanisms. 
TSH is known to regulate differentiation functions in thy-
roid cells (3-9, 12, 13). Specifically, TSH regulates the expres-
sion of thyroid-specific genes, such as Tg, TPO (6-10) and
NIS (12, 13) by modulating thyroid transcription factors.
Recent studies suggest that Pax-2/-5/-8 bind to Id proteins
and that Id proteins antagonize the activity of members of
the Pax transcription factor family (24). Thus, we investi-
gated potential functional cross-talk between Id2 and thy-
roid-specific transcription factors in both thyroid and non-
thyroid cells (Fig. 7). Id2 overexpression did not alter Tg
promoter activity in thyroid cells and did not affect TTF-1
or Pax-8-induced Tg promoter activities. These overexpres-
sion experiments suggest that Id2 does not cross-talk with
thyroid transcription factors in the regulation of Tg gene
transcription. Because thyroid transcription factors, TTF-1
and Pax-8, are not only involved in transcriptional regula-
tion, but also regulate the development of the thyroid gland
(38, 39), it is possible that Id2 cooperates with these thyroid
transcription factors in certain aspects of thyroid development.
Previous studies revealed that Id2 binds to the Rb protein
and abolishes its growth-suppressing activity (20-22). How-
ever, we found that Id2 overexpression did not alter the phos-
phorylation status of Rb in response to TSH treatment (data
not shown). The role of Id2 in TSH-mediated cell cycle reg-
ulation and thyrocyte proliferation should, therefore, be eval-
uated in future studies.
In summary, we have shown that Id2, one of the Id family
proteins, is a major target for regulation by TSH. However,
TSH-mediated Id2 expression did not alter the effects of TTF-
1 and Pax-8 on the regulation of Tg gene expression.
REFERENCES
1. Kimura T, Van Keymeulen A, Golstein J, Fusco A, Dumont JE, Roger
PP. Regulation of thyroid cell proliferation by TSH and other fac-
tors: a critical evaluation of in vitro models. Endocr Rev 2001; 22:
631-56. 
2. Cass LA, Meinkoth JL. Ras signaling through PI3K confers hor-
mone-independent proliferation that is compatible with differentia-
tion. Oncogene 2000; 19: 924-32.
3. Tsygankova OM, Saavedra A, Rebhun JF, Quilliam LA, Meinkoth
JL. Coordinated regulation of Rap1 and thyroid differentiation by
cyclic AMP and protein kinase A. Mol Cell Biol 2001; 21: 1921-9.
4. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;
296: 1655-7.
5. Suh JM, Song JH, Kim DW, Kim H, Chung HK, Hwang JH, Kim
JM, Hwang ES, Chung J, Han JH, Cho BY, Ro HK, Shong M. Reg-
ulation of the phosphatidylinositol 3-kinase, Akt/protein kinase B,
FRAP/mammalian target of rapamycin, and ribosomal S6 kinase 1
signaling pathways by thyroid-stimulating hormone (TSH) and stim-
ulating type TSH receptor antibodies in the thyroid gland. J Biol
Chem 2003; 278: 21960-71.
6. Francis-Lang H, Zannini M, De Felice M, Berlingieri MT, Fusco A,
Di Lauro R. Multiple mechanisms of interference between transfor-
mation and differentiation in thyroid cells. Mol Cell Biol 1992; 12:
5793-800.
7. Shimura H, Okajima F, Ikuyama S, Shimura Y, Kimura S, Saji M,
Kohn LD. Thyroid-specific expression and cyclic adenosine 3’5’-
monophosphate autoregulation of the thyrotropin receptor gene in-
volves thyroid transcription factor-1. Mol Endocrinol 1994; 8: 1049-
69.
8. Kohn LD, Shimura H, Shimura Y, Hidaka A, Giuliani C, Napolitano
G, Ohmori M, Laglia G, Saji M. The thyrotropin receptor. Vitam
Horm 1995; 50: 287-384.
9. Damante G, Di Lauro R. Thyroid-specific gene expression. Biochim
Biophys Acta 1994; 1218: 255-66.
10. Shimura Y, Shimura H, Ohmori M, Ikuyama S, Kohn LD. Identifi-
cation of a novel insulin-responsive element in the rat thyrotropin
receptor promoter. J Biol Chem 1994; 269: 31908-14.
11. Santisteban P, Acebron A, Polycarpou-Schwarz M, Di Lauro R. In-
sulin and insulin-like growth factor I regulate a thyroid-specific nucle-
ar protein that binds to the thyroglobulin promoter. Mol Endocrinol
1992; 6: 1310-7.
12. Endo T, Kaneshige M, Nakazato M, Ohmori M, Harii N, Onaya T.
Thyroid transcription factor-1 activates the promoter activity of rat
thyroid Na+/I- symporter gene. Mol Endocrinol 1997; 11: 1747-55.
13. Dohan O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M,
Ginter CS, Carrasco N. The Sodium/Iodide Symporter (NIS): Char-
acterization, regulation, and medical significance. Endocr Rev 2003;
24: 48-77.
14. Benezra R, Davis RL, Lockshon D, Turner DL, Weintraub H. The
protein Id: a negative regulator of helix-loop-helix DNA binding
proteins. Cell 1990; 61: 49-59.
15. Deed RW, Jasiok M, Norton JD. Nucleotide sequence of the cDNA
encoding human helix-loop-helix Id-1 protein: identification of func-Regulation of Id Proteins by TSH 269
tionally conserved residues common to Id proteins. Biochim Bio-
phys Acta 1994; 1219: 160-2.
16. Yokota Y. Id and development. Oncogene 2001; 20: 8290-8.
17. Yokota Y, Mansouri A, Mori S, Sugawara S, Adachi S, Nishikawa
S, Gruss P. Development of peripheral lymphoid organs and natu-
ral killer cells depends on the helix-loop-helix inhibitor Id2. Nature
1999; 397: 702-6.
18. Norton JD, Atherton GT. Coupling of cell growth control and apop-
tosis functions of Id proteins. Mol Cell Biol 1998; 18: 2371-81.
19. Florio M, Hernandez MC, Yang H, Shu HK, Cleveland JL, Israel
MA. Id2 promotes apoptosis by a novel mechanism independent of
dimerization to basic helix-loop-helix factors. Mol Cell Biol 1998;
18: 5435-44.
20. Iavarone A, Garg P, Lasorella A, Hsu J, Israel MA. The helix-loop-
helix protein Id-2 enhances cell proliferation and binds to the retino-
blastoma protein. Genes Dev 1994; 8: 1270-84.
21. Lasorella A, Iavarone A, Israel MA. Id2 specifically alters regula-
tion of the cell cycle by tumor suppressor proteins. Mol Cell Biol
1996; 16: 2570-8.
22. Lasorella A, Noseda M, Beyna M, Yokota Y, Iavarone A. Id2 is a
retinoblastoma protein target and mediates signaling by Myc onco-
proteins. Nature 2000; 407: 592-8. 
23. Zebedee Z, Hara E. Id proteins in cell cycle control and cellular senes-
cence. Oncogene 2001; 20: 8317-25.
24. Roberts EC, Deed RW, Inoue T, Norton JD, Sharrocks AD. Id helix-
loop-helix proteins antagonize pax transcription factor activity by
inhibiting DNA binding. Mol Cell Biol 2001; 21: 524-33.
25. Simonson MS, Rooney A, Herman WH. Expression and differen-
tial regulation of Id1, a dominant negative regulator of basic helix-
loop-helix transcription factors, in glomerular mesangial cells. Nucleic
Acids Res 1993; 21: 5767-74.
26. Kohn LD, Valente WA, Grollman EF, Aloj SM, Vitti P. Clinical
determination and/or quantification of thyrotropin and a variety of
thyroid stimulatory or inhibitory factors performed in vitro with an
improved cell line. U S Patent 1986; 4: 609-22.
27. Park ES, Kim H, Suh JM, Park SJ, Kwon OY, Kim YK, Ro HK,
Cho BY, Chung J, Shong M. Thyrotropin induces SOCS-1 (suppres-
sor of cytokine signaling-1) and SOCS-3 in FRTL-5 thyroid cells.
Mol Endocrinol 2000; 14: 440-8.
28. Kim H, Suh JM, Hwang ES, Kim DW, Chung HK, Song JH, Hwang
JH, Park KC, Ro HK, Jo EK, Chang JS, Lee TH, Lee MS, Kohn LD,
Shong M. Thyrotropin-mediated repression of class II trans-activa-
tor expression in thyroid cells: involvement of STAT3 and suppres-
sor of cytokine signaling. J Immunol 2003; 171: 616-27.
29. Bounpheng MA, Dimas JJ, Dodds SG, Christy BA. Degradation of
Id proteins by the ubiquitin-proteasome pathway. FASEB J 1999;
13: 2257-64.
30. Wojcik C. Inhibition of the proteasome as a therapeutic approach.
Drug Discov Today 1999; 4: 188-9.
31. Rui L, Fisher TL, Thomas J, White MF. Regulation of insulin/insulin-
like growth factor-1 signaling by proteasome-mediated degradation
of insulin receptor substrate-2. J Biol Chem 2001; 276: 40362-7.
32. Bounpheng MA, Melnikova IN, Dimas JJ, Christy BA. Identifica-
tion of a novel transcriptional activity of mammalian Id proteins.
Nucleic Acids Res 1999; 27: 1740-6.
33. Kaliman P, Vinals F, Testar X, Palacin M, Zorzano A. Phosphatidyli-
nositol 3-kinase inhibitors block differentiation of skeletal muscle
cells. J Biol Chem 1996; 271: 19146-51.
34. Kimura K, Hattori S, Kabuyama Y, Shizawa Y, Takayanagi J, Naka-
mura S, Toki S, Matsuda Y, Onodera K, Fukui Y. Neurite outgrowth
of PC12 cells is suppressed by wortmannin, a specific inhibitor of
phosphatidylinositol 3-kinase. J Biol Chem 1994; 269: 18961-7.
35. Sun XJ, Goldberg JL, Qiao LY, Mitchell JJ. Insulin-induced insulin
receptor substrate-1 degradation is mediated by the proteasome
degradation pathway. Diabetes 1999; 48: 1359-64.
36. Lee AV, Gooch JL, Oesterreich S, Guler RL, Yee D. Insulin-like
growth factor I-induced degradation of insulin receptor substrate 1
is mediated by the 26S proteasome and blocked by phosphatidyli-
nositol 3’-kinase inhibition. Mol Cell Biol 2000; 20: 1489-96.
37. Dere WH, Hirayu H, Rapoport B. TSH and cAMP enhance expres-
sion of the myc proto-oncogene in cultured thyroid cells. Endocrinol-
ogy 1985; 117: 2249-51.
38. Kimura S, Hara Y, Pineau T, Fernandez-Salguero P, Fox CH, Ward
JM, Gonzalez FJ. The T/ebp null mouse: thyroid-specific enhancer-
binding protein is essential for the organogenesis of the thyroid, lung,
ventral forebrain, and pituitary. Genes 1996; 10: 60-9.
39. Pasca di Magliano M, Di Lauro R, Zannini M. Pax8 has a key role
in thyroid cell differentiation. Proc Natl Acad Sci USA 2000; 97:
13144-9.